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Intercellular adhesion molecule-1 (ICAM-1) plays an important role in the recruitment of leukocytes to the endothelium, which 
causes inflammation and initiation of atherosclerosis. We have previously shown that endothelium-specific over-expression of 
class III deacetylase SIRT1 decreases atherosclerosis. We therefore addressed the hypothesis that SIRT1 suppresses ICAM-1 
expression in the endothelial cells. Here, we found that expression of SIRT1 and ICAM-1 was significantly induced by PMA 
and ionomycin (PMA/Io) in human umbilical vein endothelial cells (HUVECs). Adenovirus-mediated over-expression of 
SIRT1 significantly inhibited PMA/Io-induced ICAM-1 expression in HUVECs. Knockdown of SIRT1 by RNA interference 
(RNAi) resulted in increased expression of ICAM-1 in HUVECs. Luciferase report assay showed that over-expression of 
SIRT1 suppressed ICAM-1 promoter activity both in basic and in PMA/Io-induced conditions. We further found that SIRT1 
was involved in transcription complex binding on the ICAM-1 promoter by chromatin immunoprecipitation (ChIP) assays. 
Furthermore, SIRT1 RNAi increased NF-κB p65 binding ability to the ICAM-1 promoter by ChIP assays. Overall, these data 
suggests that SIRT1 inhibits ICAM-1 expression in endothelial cells, which may contribute to its anti-atherosclerosis effect. 
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Leukocyte recruitment and expression of pro-inflammatory 
cytokines characterize early atherogenesis and malfunction 
of inflammatory mediators mutes atheroma formation in 
mice [1]. As the first barrier of blood vessels, the endothe-
lium plays an extremely important role in maintaining ves-
sel homeostasis [2]. Various leukocyte adhesion molecules 
increase accompanied by inflammatory activation in endo-
thelial cells, which contribute to leukocyte recruitment in 
atherosclerosis-susceptible mice [3]. Thus, inhibition of 
leukocyte recruitment by decreasing the expression of adhe-
sion molecules is important for preventing initiation of ath-
erosclerosis. 
The expression of adhesion molecules such as intercellu-
lar adhesion molecule-1 (ICAM-1) is increased in athero-
sclerotic lesions [4]. Gene deletion of ICAM-1 resulted in 
significant reduction in monocyte recruitment to athero-
sclerotic lesions in ApoE-deficient mice [3]. ICAM-1 is 
upregulated in response to inflammatory stimuli such as 
interleukin-1 beta (IL-1), tumor necrosis factor-alpha 
(TNF-), LPS and PMA [5]. The divalent cation calcium 
ionophore ionomycin (Io) interacts synergistically with 
PMA but not with cytokines or LPS in upregulating 
ICAM-1 [5]. The combination of PMA and Io (PMA/Io) is 
routinely used as a T-cell receptor (TCR)-independent 
model to study T-cell activation and proliferation. PMA/Io 
mimics the phospholipase C-driven activation of protein 
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kinase C and cytosolic Ca2+ increase and induces activation 
of NF-B, NFAT and AP-1. NF-B is of special interest in 
endothelial cells since it drives the expression of important 
adhesion molecules, such as ICAM-1, which recruit blood 
monocytes to atherosclerotic lesions [6]. NFAT cooperated 
with NF-B to regulate thrombin-induced ICAM-1 gene 
expression by binding to the intronic NF-κB site in the 
ICAM-1 gene [7]. 
SIRT1, a well-known mammalian sirtuin, is involved in 
aging and age-related diseases [8]. SIRT1 has been de-
scribed as a “guardian at the gates of adipose tissue inflam-
mation”, playing an important role in anti-inflammatory 
processes [9]. SIRT1 inhibits inflammatory pathways in 
macrophages and modulates insulin sensitivity [10]. SIRT1 
acts to protect the heart from hypertrophy, metabolic 
dysregulation and inflammation [11]. Moreover, SIRT1 
inhibits NF-B and AP-1 transcriptional activity and the 
expression of downstream inflammatory genes [12–15]. We 
have previously shown that transgenic mice that over-      
express SIRT1 in the vascular endothelium have better en-
dothelium-dependent vasodilation and fewer atherosclerotic 
lesions when fed a high-fat diet [16]. Recently, expression 
of ICAM-1 was increased in atherosclerotic plaques of Ap-
oE/SIRT1+/ compared with ApoE/SIRT1+/+ mice [17]. 
However, the mechanism by which SIRT1 regulates 
ICAM-1 expression remains unknown.  
In the present study, we found that over-expression of 
SIRT1 significantly decreased PMA/Io-induced ICAM-1 
expression in human umbilical vein endothelial cells (HU-
VECs). Knockdown of SIRT1 by RNA interference (RNAi) 
remarkably up-regulated ICAM-1 expression in HUVECs. 
Moreover, we found that SIRT1 significantly inhibited both 
basic and PMA/Io-induced ICAM-1 promoter activity. 
SIRT1 was involved in transcription complex binding on 
the ICAM-1 promoter by chromatin immunoprecipitation 
(ChIP) assays. Furthermore, SIRT1 RNAi increased NF-B 
p65 binding ability to the ICAM-1 promoter by ChIP assays. 
These data suggests that SIRT1 inhibits ICAM-1 expression 
in endothelial cells, which may contribute to its an-
ti-atherosclerosis effect. 
1  Materials and methods 
1.1  Drugs 
PMA (Cat #P1585), Ionomycin (Cat #I0634), Cyclosporin 
A (Cat #C1832), resveratrol (Cat #R5010) and Sirtinol (Cat 
#S7942) were purchased from Sigma-Aldrich.  
1.2  Plasmids, HUVECs culture and adenovirus gener-
ation 
SIRT1 expression vector is a gift from Dr. Ishikawa [18]. 
Endothelial cells were freshly isolated from human umbili-
cal cord veins as described previously [16] and cultured in 
M200 medium (Cascade Biologics Inc., Portland, Oregon, 
USA). The growth medium was changed every two days 
until >80% cells reached confluence. Cells between the 3rd 
and the 6th passages were grown in mono-layers in a hu-
midified atmosphere of 5% CO2 at 37°C, and used for ex-
periments at >80% confluence. Replication-defective ad-
enoviral vectors expressing SIRT1 (Ad-SIRT1) or a green 
fluorescent protein control (Ad-GFP) were prepared using 
the AdEasy vector kit (Quantum Biotechnologies) as de-
scribed in the supplier’s protocol. The adenovirus-    
mediated knockdown of SIRT1 (Ad-SIRT1 RNAi) and a 
control vector (Ad-U6) were generated using the same 
system. HUVECs were infected with the above adenovirus 
for 24 h and were cultured in fresh M200 medium for fur-
ther treatment.  
1.3  Reverse transcription and real-time PCR 
Total RNA was extracted from cells using Trizol (Invitro-
gen) according to the manufacturer’s instructions. Two mi-
crograms of total RNA were used to synthesize first-strand 
cDNA with M-MuLV reverse transcriptase (New England 
BioLabs) using random primers. Real-time PCR was per-
formed using the BioRad iCycler iQ5 Real-Time PCR De-
tection System with the Quantitect SYBR Green One-Step 
RT-PCR Kit (QIAGEN). Fluorescence curves were ana-
lyzed with iCycler iQ5 Optical System Software (version 
2.0). Primer sequences for specific genes are presented in 
Table S1.  
1.4  Western blotting analysis 
HUVEC protein was extracted with Radioimmunoprecipita-
tion Assay (RIPA) buffer (25 mmol L1 Tris-HCl pH 7.6, 
150 mmol L1 NaCl, 1% NP-40, 1% sodium deoxycholate 
and 0.1% SDS). After lysis on an ice for 0.5 h, samples 
were sonicated and centrifuged at 4°C at 12000 r min1 for 
0.5 h. The supernatants were transferred into fresh tubes and 
protein concentrations were determined by the bicincho-
ninic acid (BCA) method. Equal amounts of protein (20 
g/lane) were separated by SDS-PAGE and transferred onto 
polyvinylidene difluoride membranes (Millipore). After 
being blocked, the filters were incubated with the following 
primary antibodies: anti-SIRT1 (Santa Cruz Biotechnology, 
Cat #sc-15404), anti-ICAM-1 (Cell Signal Technology, Cat 
#4915). After being washed and incubated with the appro-
priate horseradish peroxidase-conjugated secondary anti-
body (Santa Cruz Biotechnology), the immune complexes 
were visualized with a chemiluminescence reagent. Western 
blotting was quantified densitometrically with Quantity One 
software (Bio-Rad), and the intensity values were normal-
ized to anti-GAPDH.  
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1.5  Transfection and luciferase assays 
HEK293 cells were grown as recommended by ATCC and 
were transfected with Lipofectamine 2000 (Invitrogen) ac-
cording to the manufacturer’s instructions. Luciferase as-
says were performed using a dual luciferase reporter assay 
system (Promega). Luciferase activity was normalized by 
transfection efficiency using pRL-CMV reporter (Promega) 
as an internal control. The results are expressed as percent-
ages of relative luciferase activity of the control group. 
1.6  ChIP 
Chromatin immunoprecipitation (ChIP) assays were per-
formed in HUVECs as described [19]. A rabbit polyclonal 
antibody for SIRT1 (Santa Cruz Biotechnology, Cat 
#sc-15404) was used in ChIP assay. Control immunoprecip-
itations were carried out with nonimmune normal rabbit IgG 
(Santa Cruz Biotechnology, Cat #sc-2027). 
1.7  Statistical analysis 
Data are expressed as mean±SD. Statistical analyses were 
performed using the two-tailed unpaired Student’s t-test to 
determine statistical significances between the groups. A 
P-value less than 0.05 was considered significant. 
2  Results 
2.1  SIRT1 and ICAM-1 expression is induced by 
PMA/Io in HUVECs 
Considering that the ICAM-1 promoter has binding sites for 
NF-B, NFAT and AP-1, we treated HUVECs with PMA/Io, 
which is known to induce activation of transcription factors 
NF-B, NFAT and AP-1. Previous studies have shown that 
ionomycin (Io) interacted synergistically with PMA in up-
regulating ICAM-1 expression [5]. Here we repeated the 
results and found that ICAM-1 mRNA expression level was 
induced higher by PMA than by Io (Figure 1B). In contrast, 
SIRT1 mRNA level was significantly induced about to 
3-fold by Io, but was not significantly changed by PMA 
(Figure1A). The results showed that an Io-activated caci-
um-calcineurin-NFAT signal pathway played an important 
role in inducing SIRT1 expression. Io also interacted syner-
gistically with PMA in inducing SIRT1 mRNA expression 
level about 3.6-fold (Figure 1A). Moreover, SIRT1 and 
ICAM-1 protein expression was also induced by PMA/Io in 
HUVECs (Figure 1C and D). 
2.2  Over-expression of SIRT1 suppresses ICAM-1 ex-
pression in PMA/Io-treated HUVECs  
To study the effect of increased expression of SIRT1 on  
 
Figure 1  SIRT1 and ICAM-1 expression is significantly induced in 
HUVECs treated with PMA/Io. A and B, HUVECs were treated with PMA 
(10 ng mL1), Io (0.25 mol L1) or PMA/Io (10 ng mL1 PMA plus 0.25 
mol L1 Io), vehicle DMSO for 3 h. Total RNA was isolated and mRNA 
expression level for SIRT1 (A) and ICAM-1 (B) was analyzed by real-time 
PCR analysis. Data shown represent the mean±SD of triplicate samples of 
one representative of total three independent experiments. Relative mRNA 
unit is calculated by using actin as a reference gene. *, P<0.05; **, P<0.01. 
C and D, HUVECs were treated with PMA/Io (10 ng mL1 PMA plus 0.25 
mol L1 Io) for 3 h. Protein expression was analyzed by Western blotting. 
Bar graphs show densitometric analysis of immunoblots of SIRT1 (C) and 
ICAM-1(D) protein. Data are presented as mean±SD of SIRT1/GAPDH 
and ICAM-1/ GAPDH expression ratio (n=3). Immunoblots of SIRT1, 
ICAM-1 and GAPDH are representative of three independent experiments. 
*, P<0.05; **, P<0.01. 
ICAM-1 expression, we over-expressed SIRT1 in PMA/Io-      
treated HUVECs. We found that over-expression of SIRT1 
suppressed PMA/Io-induced expression of both ICAM-1 
mRNA and protein in HUVECs to 60% and 50%, respec-
tively (Figure 2A). Similarly, SIRT1 activator resveratrol 
(RSV) suppressed ICAM-1 protein expression to 18% (Fig-
ure 2B). 
To detect whether NFAT inhibition influences the sup-
pressive effect of SIRT1 on ICAM-1 expression, we 
over-expressed SIRT1 in PMA/Io-treated HUVECs both in 
the presence and absence of NFAT inhibitor Cyclosporin A 
(CsA). We found that over-expression of SIRT1 suppressed 
ICAM-1 protein expression in HUVECs induced by 
PMA/Io either in presence or absence of CsA to 44% and 
53%, respectively (Figure 2C). The results showed that 
there was no significant effect of CsA on inhibition of 
ICAM-1 expression by SIRT1. 
2.3  Knockdown of SIRT1 upregulates ICAM-1 expres-
sion in HUVECs  
To examine the effect of SIRT1 knockdown on ICAM-1 
expression, we infected HUVECs with adenoviral vectors 
encoding SIRT1 RNAi (Ad-SIRT1 RNAi) or control (Ad- 
U6). Knockdown of SIRT1 by RNA interference (RNAi)  
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Figure 2  Over-expression of SIRT1 suppresses ICAM-1 expression in 
HUVECs treated with PMA/Io. A, HUVECs infected with adenoviral 
vectors encoding SIRT1 (Ad-SIRT1) or control Ad-GFP were treated with 
PMA/Io (10 ng mL1 PMA plus 0.25 mol L1 Io) for 3 h. Total RNA was 
isolated and mRNA level for ICAM-1 was analyzed by real-time PCR 
analysis (left). Relative mRNA unit is calculated by using actin as a refer-
ence gene. Protein expression was analyzed by Western blotting (right). 
Bar graphs show densitometric analysis of immunoblots of ICAM-1 pro-
tein. Data are presented as the mean±SD of ICAM-1/GAPDH expression 
ratio (n=3). Immunoblots of ICAM-1 and GAPDH are representative of 
three independent experiments. **, P<0.01. B, HUVECs were pretreated 
with resveratrol (RSV) (30 mol L1) or vehicle DMSO for 1 h, then treat-
ed with PMA/Io (10 ng mL1 PMA plus 0.25 mol L1 Io) for another 3 h. 
Protein expression was analyzed by Western blotting. Bar graphs show 
densitometric analysis of immunoblots of ICAM-1 protein. Data are pre-
sented as the mean±SD of ICAM-1/GAPDH expression ratio (n=3). Im-
munoblots of ICAM-1 and GAPDH are representative of three independent 
experiments. **, P<0.01. C, HUVECs infected with adenoviral vectors 
encoding SIRT1 (Ad-SIRT1) or control Ad-GFP for 24 h, then pretreated 
with CsA (1 mol L1) or vehicle DMSO for 1 h and treated with PMA/Io 
(10 ng mL1 PMA plus 0.25 mol L1 Io) for another 3 h. Protein expres-
sion was analyzed by Western blotting. Bar graphs show densitometric 
analysis of immunoblots of ICAM-1 protein. Data are presented as the 
mean±SD of ICAM-1/GAPDH expression ratio (n=3). Immunoblots of 
ICAM-1 and GAPDH are representative of three independent experiments. 
**, P<0.01. 
upregulated ICAM-1 expression at both the mRNA and pro-
tein levels in HUVECs to 2-fold and 3-fold, respectively 
(Figure 3A). Similarly, SIRT1 inhibitor Sirtinol significantly 
upregulated ICAM-1 expression in HUVECs to 37.5-fold 
(Figure 3B).  
2.4  SIRT1 inhibits ICAM-1 promoter activity induced 
by PMA/Io 
To further examine whether SIRT1 inhibits ICAM-1 pro-
moter activity, we performed assays using luciferase report-
er containing the ICAM-1 promoter (ICAM-1-Luc). Lucif-
erase report assay showed that over-expression of SIRT1 
suppressed ICAM-1 promoter activity both in basic and 
PMA/Io-induced conditions (Figure 4). 
2.5  SIRT1 is involved in transcription complex binding 
on the ICAM-1 promoter in HUVECs 
The first 1.3 kb upstream of the ICAM-1 transcription start 
site are required for ICAM-1basal expression and regulation 
by inflammatory stimuli [20]. To explore whether SIRT1is 
involved in transcription complex binding on the ICAM-1 
promoter, we performed ChIP assays in HUVECs on a 1.3 
kb region of the ICAM-1 promoter upstream of the tran-
scription start site, using semiquantitative PCR (qPCR) with 
primers for regions (R) named 1 (1297 to 1020 bp); 2 
(1033 to 793 bp); 3 (814 to 551 bp); 4 (577 to 271 
bp); and 5 (287 to +16 bp). This showed that an increase in 
the amount of SIRT1 bound to R5, compared with the oth-
ers regions (Figure 5A). These data indicated that SIRT1 
was involved in transcription complex binding on the 
ICAM-1 promoter in a region detected by the R5 primers 
(287 to +16 bp). 
NF-B is deacetylated and transcriptionally suppressed 
by SIRT1 and binds at site 187 to 178 bp of the ICAM-1 
promoter [12,21]. To examine whether NF-κB is involved 
in the effect of SIRT1 on regulating expression of ICAM-1, 
we detected NF-B p65 binding ability on ICAM-1 pro-
moter region 5 (287 to +16 bp) by ChIP analysis. As 
shown in Figure 5, SIRT1 RNAi increases NF-B p65 
binding ability on ICAM-1 promoter region 5 (Figure 5B). 
3  Discussion 
Here, we found that expression of SIRT1 and ICAM-1 was 
significantly increased by PMA/Io in HUVECs. Over-       
expression of SIRT1 significantly inhibited PMA/Io- in-
duced ICAM-1 expression in HUVECs. Moreover, SIRT1 
suppressed ICAM-1 promoter activity both in basic and 
PMA/Io stimulated conditions. We also found that SIRT1 
was involved in transcription complex binding on the 
ICAM-1 promoter by ChIP assays. Furthermore, SIRT1 
RNAi increased NF-B p65 binding ability to the ICAM-1 
promoter by ChIP assays. 
SIRT1 has been pointed as a key regulator of vascular 
endothelial homeostasis controlling angiogenesis, vascular 
tone and endothelial dysfunction [22]. More evidence has 
pointed out that SIRT1 is a key inducible factor in response 
to inflammatory stimulation. For example, we have previ-
ously shown that oxLDL and H2O2 treatment increased 
SIRT1 protein levels in HUVECs [16,18], and TNF--      
induced SIRT1 expression in vascular smooth muscle cells  
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Figure 3  Knockdown of SIRT1 upregulates ICAM-1 expression in HUVECs. A, HUVECs were infected with adenoviral vectors SIRT1 RNAi (Ad-SIRT1 
RNAi) or control Ad-U6. Total RNA was isolated and mRNA level for ICAM-1 was analyzed by real-time PCR analysis (left). Data shown represent the 
mean±SD of triplicate samples of one representative of total three independent experiments. Relative mRNA unit is calculated by using GAPDH as a refer-
ence gene. Protein expression was analyzed by Western blotting (right). Bar graphs show densitometric analysis of immunoblots of ICAM-1 protein. Data 
are presented as the mean±SD of ICAM-1/GAPDH expression ratio (n=3). Immunoblots of ICAM-1 and GAPDH are representative of three independent 
experiments. **, P<0.01. B, HUVECs were treated with Sirtinol (25 mol L1) or vehicle DMSO for 1 h. Total RNA was isolated and mRNA level for 
ICAM-1 was analyzed by real-time PCR analysis. Data shown represent the mean±SD of triplicate samples of one representative of total three independent 
experiments. Relative mRNA unit is calculated by using actin as a reference gene. **, P<0.01. 
 
 
Figure 4  Over-expression of SIRT1 suppresses ICAM-1 promoter activ-
ity. HEK293 cells were transiently transfected with 0.1 g ICAM-1 lucif-
erase reporter (ICAM-1-Luc), 30 ng pRL-CMV, and 0.3 g SIRT1 expres-
sion vectors or control (pcDNA3.1) for 24 h, then treated with PMA/Io (10 
ng mL1 PMA plus 0.25 mol L1 Io) or vehicle DMSO for 3 h. The relative 
luciferase activities are presented as mean±SD of triplicate samples and are 
representative of three independent experiments. **, P<0.01. 
 
(VSMCs) [23]. Here, we found that the SIRT1 level was 
induced by PMA/Io in HUVECs. It suggests that SIRT1 has 
a compensatory upregulation in endothelial cells in response 
to inflammatory factors. Moreover, expression of ICAM-1 
was found to be increased in atherosclerotic plaques of 
ApoE/SIRT1+/ mice compared with ApoE/ SIRT1+/+ 
mice [17]. Furthermore, we demonstrated that SIRT1 sig-
nificantly inhibited PMA/Io-induced ICAM-1 expression in 
HUVECs to 50%. Overall, these data suggests that SIRT1 
inhibits ICAM-1 expression in the endothelial cells, which 
may contribute to its anti-atherosclerosis effect. 
The combination of PMA and Io activated these signals 
that mimic the phospholipase C-driven activation of protein 
kinase C and increase in cytosolic Ca2+ and induce the tran-
scription factors NF-B, NFAT and AP-1. Our previous 
work demonstrated SIRT1 suppresses the transcriptional 
activity of AP-1 [15]. Moreover, SIRT1 inhibits NF-B 
transcriptional activity [12]. NF-B plays essential roles in 
transcriptional regulation of ICAM-1 in endothelial cells 
and binds at site 187 to 178 bp of the ICAM-1 promoter 
[21]. In addition, ERK, JNK, AP-1 and NF-κB are all in-
volved in interleukin-1-beta-induced ICAM-1 expression 
enhancing leukocyte adhesion in human rheumatoid arthritis 
synovial fibroblasts [24]. We found that SIRT1 bound the 
ICAM-1 promoter at the R5 region (287 to +16 bp) and 
NF-B was included in the region. Moreover, SIRT1 inhib-
its PMA/Io induced NF-B transcriptional activity and 
ICAM-1 promoter activity. SIRT1 is involved in transcrip-
tion complex binding on the ICAM-1 promoter and SIRT1 
RNAi increases NF-B p65 binding ability to the ICAM-1 
promoter. The data indicated that suppressive effect of 
SIRT1 on ICAM-1 expression was at least partly mediated 
by NF-B. In addition, NFAT cooperates with NF-B by 
binding to the intronic NF-B site on the ICAM-1 gene [7]. 
Our findings demonstrated that over-expression of SIRT1 
inhibited ICAM-1 expression in PMA/Io-treated HUVECs 
both in the presence and absence of NFAT inhibitor CsA, 
although the extent of inhibition was not of statistical sig-
nificance (44% and 53%, respectively). This indicated that 
NFAT inhibition may not influence the effect of SIRT1 on 
inhibition of ICAM-1 expression.  




Figure 5  SIRT1 is involved in transcription complex binding on the ICAM-1 promoter. A, ChIP assays were performed with chromatin prepared from 
HUVECs. Chromatin was immunoprecipitated with normal rabbit IgG or antibody against SIRT1, and precipitated genomic DNA was an analyzed by semi-
quantitative PCR using primers for the specific ICAM-1 promoter region, respectively. B, HUVECs were infected with adenoviral vectors encoding SIRT1 
RNAi (Ad-SIRT1 RNAi) or control Ad-U6 for 24 h. ChIP assays were performed with chromatin prepared from HUVECs. Chromatin was immunoprecipi-
tated with normal rabbit IgG, antibody against p65, and precipitated genomic DNA was analyzed by semiquantitative PCR using primers for the specific 
ICAM-1 promoter region 5 (287 to +16 bp). 
 
In conclusion, our data provide evidence that SIRT1 sig-
nificantly inhibited PMA/Io-induced ICAM-1 expression in 
endothelial cells. Therefore, inhibition of ICAM-1 expres-
sion by activation of SIRT1 may be a potential therapeutic 
strategy for inflammation in atherosclerosis. 
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Supporting Information 
Figure S1  Over-expression of SIRT1 suppresses PMA/Io induced NF-κB transcriptional activity. HEK293 cells were transiently transfected with 0.1 g 
NF-B luciferase reporter (NF-B-Luc), 30 ng pRL-CMV and 0.3 g of SIRT1 expression vectors or control (pcDNA3.1) for 24 h, then treated with 
PMA/Io (10 ng/ml PMA plus 0.25 M Io) or vehicle DMSO for 3 h. The relative luciferase activities are presented as the mean ± SD of triplicate samples 
and are representative of three independent experiments. **, P<0.01. 
Table S1 Oligonucleotide sequences used in this study 
The supporting information is available online at life.scichina.com and www.springerlink.com. The supporting materials 
are published as submitted, without typesetting or editing. The responsibility for scientific accuracy and content remains en-
tirely with the authors. 
 
 
